Baxter International Inc. Posts Strong Q2 Earnings, Raises 2026 Guidance

BAX shares jumped roughly 17% after the company posted second-quarter 2026 sales of $2.96 billion, up 5.3% year over year and ahead of Wall Street's estimate, alongside adjusted earnings per share of $0.56 that came in well above the roughly $0.37 consensus.

The scale of the beat, more than 50% above the EPS estimate, is notable for a company that has spent the past two years working through a post-divestiture restructuring following its Kidney Care and Vantive separation. A quarter this far ahead of expectations suggests the turnaround work may be translating into cleaner execution rather than one-time cost benefits.

Baxter followed the results by raising its full-year 2026 adjusted EPS guidance to $1.95-$2.15, up from a prior $1.85-$2.05 range. The company also lifted its full-year sales guidance to $11.58-$11.69 billion from $11.24-$11.36 billion, and now expects reported sales growth of 3%-4% for the year, up from a prior 1% estimate. Management pointed to strong demand for the company's IV solutions as a contributor to the improved outlook.

The combined raise on both earnings and revenue, alongside a reaffirmed leverage target, suggests Baxter's balance-sheet repair is proceeding alongside the operational improvement rather than at its expense. Investors may watch whether the IV-solutions demand driving part of the beat persists into the back half of the year, and whether the company's leverage trajectory stays on track as guidance climbs.